Charles J Homcy has sold stock and made no open-market buys since Mar 2017

Charles J. Homcy, M.D. is a biotechnology executive, venture capitalist, and physician who serves as Chairman of Pharmaceuticals and Lead Director on the board of BridgeBio Pharma, Inc., where he has been a director since 2018 and chairman of pharmaceuticals since 2019.( As a corporate insider at BridgeBio, he has reported multiple equity transactions, including significant share sales and grants of restricted stock units and stock options tied to his continued board service.( He is also recognized as a founder of BridgeBio Pharma, reflecting his long-standing role in shaping the company’s strategic direction and pharmaceutical programs.(

Dr. Homcy is Partner Emeritus and Special Advisor at Third Rock Ventures, focusing on building biotech companies developing novel therapeutic approaches.( He previously co‑founded Portola Pharmaceuticals and served as its president and chief executive officer, and earlier led research and development at Millennium Pharmaceuticals following its acquisition of COR Therapeutics, where he was executive vice president of R&D and a director.( His board and advisory roles have included Maze Therapeutics, Global Blood Therapeutics, CytomX Therapeutics, Ambys Medicines, and multiple other life‑science companies.( A trained physician-scientist, Homcy has held clinical and academic positions as a clinical professor of medicine at the University of California, San Francisco, and attending physician at the San Francisco VA Medical Center, and he earned both his A.B. and M.D. degrees from Johns Hopkins University, where he now serves as a trustee.(

Written by Perplexity from public sources.